NREP
NEW REPRESENTATIVE AT IB RECEIVED
04/28/2024
Back to search
Official data from USPTO
PSARLINK
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
30
Latest update
04/28/2024
Trademark type
Word
Nice classes
1, 5
Filing date
07/15/2020
Registration date
10/26/2021
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
10/26/2021
Last transaction
03/14/2024
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
34
Owner location
FR
Examiner
PEISECKI, MARK
Law office
L50
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
M. B. (pessoa física)
Representatives
John R. Rudolph Eli Lilly and Company
Technical classification
Nice Classes
Class 1Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Chemicalbiochemicalbiological and biotechnological preparations for use in industry and science ; chemical substances for the manufacture of pharmaceutical products for non-medical purposesfor use in manufacturing of antibody conjugates ; chemical substances for tethering moleculesin particular chemical substances for tethering molecules for cancer therapyfor research in active substances and medicines other than for medical or veterinary purposes; chemical substances for the formation of antibody conjugates for use in laboratoriesother than for medical or veterinary purposes ; chemical reagents for scientific purposes other than for medical or veterinary purposes; reagents for scientific or medical research; chemicalbiochemical and biological reagents for scientific or medical research use; chemicals for bioconjugationreversible cysteine protectionsurface modificationthe production of prodrugs for use in laboratoriesother than for medical or veterinary purposes; antibodies and antibody conjugates for scientific purposesother than for medical or veterinary purposes; antibodies for scientific or medical research; molecules and biomoleculesreagentsantibody fragmentsantibodiesall intended for fundamental research and developmentmedical research and scientific diagnosis; Diagnostic products for scientific or research use related to conjugated antibodiesdiagnostic preparations for scientific use
Class 5
Pharmaceutical preparations for the treatment of cancer ; pharmaceutical products for the prevention or treatment of human diseasesthe treatment of cancer; chemicalbiological and biochemical products for medical and pharmaceutical useantibody-drug conjugates and any protein combined with a druga polynucleotideanother proteina chemical entityanother functional entityused as medical binders or fillers; pharmaceutical preparationsnamely bioconjugatesintended for the diagnosis and treatment of diseasescancer ; antibody productsantibody or protein bioconjugates for the medical diagnosis and treatment of cancerantibody/protein drug conjugatesantibody/protein labeled conjugates and antibody/protein imaging agent conjugates; delivery devices for antibodiesdrugs delivery agent in the form of antibodies drug conjugates that facilitate the delivery and action of medical preparations ; molecules and biomoleculesreagentsantibody fragmentsantibodiesall intended for medical diagnosis and disease treatment; pharmaceutical productspreparations and medical articlesantibodiesantibody conjugates and active principles and antibody conjugates for medical purposes; chemical reagents for medical usechemical reagents to bind molecules for medical use; chemical reagents for the functionalization of biomolecules for medical use
Publications
History of USPTO decisions and trademark events.
30 publications found
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
03/14/2024
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
03/14/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
03/14/2024
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
03/14/2024
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
03/14/2024
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
05/09/2022
FICS
FINAL DISPOSITION NOTICE SENT TO IB
04/18/2022
FIMP
FINAL DISPOSITION PROCESSED
04/18/2022
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
01/26/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
10/26/2021
GPNX
NOTIFICATION PROCESSED BY IB
08/15/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
08/10/2021
PUBO
PUBLISHED FOR OPPOSITION
08/10/2021
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
07/28/2021
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
07/28/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
07/21/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
07/05/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
06/24/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
06/24/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
06/24/2021
RFNT
REFUSAL PROCESSED BY IB
01/24/2021
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
01/05/2021
RFRR
REFUSAL PROCESSED BY MPU
01/05/2021
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
12/19/2020
CNRT
NON-FINAL ACTION WRITTEN
12/18/2020
MAFR
APPLICATION FILING RECEIPT MAILED
12/18/2020
DOCK
ASSIGNED TO EXAMINER
12/14/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
12/14/2020
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
12/10/2020
Continuous trademark protection
Get notified about every new filing that threatens PSARLINK or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.